Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ELVN

Enliven Therapeutics Inc

Dec 11 • 04:00PM ET

24.08

Dollar change +0.29
Percentage change 1.22	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ALNY IONS BMRN INCY NBIX PRTA EXEL BGNE

| Held by: VTI IWM VXF IWO IBB VTWO SCHA IWC VHT IHE

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.91	Insider Own	38.12%	Shs Outstand	47.25M	Perf Week	1.56%
Market Cap	1.18B	Forward P/E	-	EPS next Y	-2.28	Insider Trans	-1.64%	Shs Float	30.23M	Perf Month	-12.85%
Income	-85.21M	PEG	-	EPS next Q	-0.52	Inst Own	67.65%	Short Float	22.85%	Perf Quarter	7.84%
Sales	0.00M	P/S	-	EPS this Y	5.20%	Inst Trans	-2.21%	Short Ratio	27.10	Perf Half Y	5.85%
Book/sh	6.10	P/B	3.95	EPS next Y	-19.71%	ROA	-29.41%	Short Interest	6.91M	Perf Year	121.53%
Cash/sh	5.97	P/C	4.03	EPS next 5Y	-	ROE	-30.98%	52W Range	9.80 - 30.03	Perf YTD	73.99%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.16%	ROI	-29.55%	52W High	-19.81%	Beta	1.02
Dividend TTM	-	Quick Ratio	17.44	Sales past 5Y	0.00%	Gross Margin	-	52W Low	145.71%	ATR (14)	1.43
Dividend Ex-Date	-	Current Ratio	17.44	EPS Y/Y TTM	-159.81%	Oper. Margin	-	RSI (14)	43.48	Volatility	6.25% 6.24%
Employees	46	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.12	Target Price	37.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	5.24%	Payout	-	Rel Volume	0.77	Prev Close	23.79
Sales Surprise	-	EPS Surprise	3.40%	Sales Q/Q	-	Earnings	Nov 13 AMC	Avg Volume	254.92K	Price	24.08
SMA20	-2.38%	SMA50	-9.78%	SMA200	6.63%	Trades		Volume	196,703	Change	1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-24	Initiated	H.C. Wainwright	Buy	$37
Jun-11-24	Initiated	Robert W. Baird	Outperform	$32
Apr-09-24	Initiated	Mizuho	Buy	$34
Mar-29-23	Initiated	Jefferies	Buy	$27

Nov-13-24 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire) -5.04%
Nov-07-24 04:05PM	Enliven Therapeutics to Present at the Jefferies London Healthcare Conference (PR Newswire)
Oct-18-24 04:38PM	Why this largely unknown company is one analyst's top biotech pick (Yahoo Finance Video)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +7.92%
Sep-30-24 04:52AM	Enliven Therapeutics ELVN-001 shows promise in Phase I CML trial (Clinical Trials Arena) +5.84%
09:35AM	Loading…
Sep-28-24 09:35AM	Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Sep-26-24 08:50AM	Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going (Zacks)
Sep-18-24 04:05PM	Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML (GlobeNewswire) +6.02%
Sep-09-24 02:05PM	Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst (Benzinga) +7.28%
Sep-04-24 09:55AM	Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? (Zacks)
Aug-16-24 09:55AM	Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet (Zacks)
Aug-13-24 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (GlobeNewswire)
May-29-24 04:05PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) -8.14% +5.67%
May-20-24 05:06PM	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing (MT Newswires)
May-14-24 10:54PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:01PM	Loading…
05:01PM	Enliven Therapeutics Q1 Loss Narrows (MT Newswires)
04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (GlobeNewswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-11-24 03:44PM	Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program (Benzinga) +20.18%
07:55AM	Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Apr-09-24 04:05PM	Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 (GlobeNewswire) -5.58% +7.45%
Mar-23-24 01:51AM	Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares (GuruFocus.com)
Mar-19-24 08:30AM	Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates (GlobeNewswire) +38.77%
Mar-14-24 09:53PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.95%
04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-27-24 04:05PM	Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Jan-03-24 09:01AM	Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares (GuruFocus.com)
Nov-09-23 04:05PM	Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -7.97%
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace) +6.00%
04:05PM	Loading…
Aug-10-23 04:05PM	Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-31-23 04:55PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.85%
May-11-23 04:05PM	Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Nov 27 '24	Option Exercise	2.48	5,250	13,020	5,250	Dec 02 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Nov 27 '24	Sale	24.89	5,250	130,688	0	Dec 02 05:18 PM
Patel Anish	Member of immediate family of	Nov 15 '24	Proposed Sale	24.92	17,500	436,100		Nov 15 04:35 PM
Patel Anish	Member of immediate family of	Nov 15 '24	Proposed Sale	24.92	17,500	436,100		Nov 15 04:28 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 28 '24	Option Exercise	2.48	6,250	15,500	6,250	Oct 30 06:04 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 28 '24	Sale	28.56	6,250	178,485	0	Oct 30 06:04 PM
Patel Anish	CHIEF OPERATING OFFICER	Oct 18 '24	Sale	30.00	716	21,483	343,311	Oct 22 04:23 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 18 '24	Sale	30.00	847	25,413	1,015,188	Oct 22 04:22 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 18 '24	Sale	30.00	924	27,723	1,002,892	Oct 22 04:21 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 18 '24	Option Exercise	2.48	814	2,019	814	Oct 22 04:19 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 18 '24	Sale	30.00	814	24,422	0	Oct 22 04:19 PM
Heyman Richard A.	Director	Oct 18 '24	Sale	30.00	817	24,512	123,673	Oct 22 04:18 PM
Heyman Richard A.	Director	Oct 18 '24	Sale	30.00	753	22,592	27,165	Oct 22 04:18 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Oct 18 '24	Option Exercise	2.48	816	2,024	816	Oct 22 04:17 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Oct 18 '24	Sale	30.00	816	24,482	0	Oct 22 04:17 PM
Patel Anish	Officer	Oct 18 '24	Proposed Sale	28.02	50,000	1,401,000		Oct 18 06:42 PM
Lyssikatos Joseph P	Officer	Oct 18 '24	Proposed Sale	28.02	65,000	1,821,300		Oct 18 05:42 PM
Heyman Richard A.	Director	Oct 18 '24	Proposed Sale	28.02	1,566	43,879		Oct 18 05:27 PM
Kintz Samuel	Officer	Oct 18 '24	Proposed Sale	28.02	91,123	2,553,266		Oct 18 05:17 PM
Heyman Richard A.	Director	Oct 18 '24	Proposed Sale	28.02	12,165	340,863		Oct 18 05:10 PM
Hohl Benjamin	Officer	Oct 18 '24	Proposed Sale	28.02	13,000	364,260		Oct 18 05:00 PM
Collins Helen Louise	Officer	Oct 18 '24	Proposed Sale	28.02	25,000	700,500		Oct 18 04:57 PM
Heyman Richard A.	Director	Oct 15 '24	Sale	27.67	1,270	35,143	124,490	Oct 17 05:06 PM
Heyman Richard A.	Director	Oct 15 '24	Proposed Sale	27.75	1,270	35,242		Oct 15 04:38 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 09 '24	Sale	28.16	37,878	1,066,561	1,016,035	Oct 10 08:39 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 08 '24	Sale	27.97	13,267	371,024	1,053,913	Oct 10 08:39 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 09 '24	Sale	28.15	16,710	470,405	1,003,816	Oct 10 08:38 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 08 '24	Sale	27.96	13,267	370,929	1,020,526	Oct 10 08:38 PM
Ballal Rahul D.	Director	Oct 08 '24	Option Exercise	14.10	10,420	146,925	32,761	Oct 10 08:36 PM
Ballal Rahul D.	Director	Oct 08 '24	Sale	28.17	10,420	293,557	22,341	Oct 10 08:36 PM
Lyssikatos Joseph P	Officer	Oct 09 '24	Proposed Sale	28.01	12,000	336,120		Oct 09 04:27 PM
Kintz Samuel	Officer	Oct 09 '24	Proposed Sale	28.01	12,000	336,120		Oct 09 04:16 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 04 '24	Sale	27.51	7,522	206,937	1,069,887	Oct 08 06:58 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 07 '24	Sale	27.61	2,707	74,727	1,067,180	Oct 08 06:58 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 04 '24	Sale	27.51	12,206	335,792	1,036,523	Oct 08 06:57 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 07 '24	Sale	27.50	2,730	75,075	1,033,793	Oct 08 06:57 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 04 '24	Option Exercise	2.48	10,218	25,341	10,218	Oct 08 06:56 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 07 '24	Option Exercise	2.48	1,270	3,150	2,000	Oct 08 06:56 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 04 '24	Sale	27.51	10,218	281,079	0	Oct 08 06:56 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 07 '24	Sale	27.51	1,270	34,935	0	Oct 08 06:56 PM
Heyman Richard A.	Director	Oct 04 '24	Sale	27.51	2,825	77,704	125,760	Oct 08 06:54 PM
Ballal Rahul D.	Director	Oct 08 '24	Proposed Sale	27.45	10,420	286,029		Oct 08 03:59 PM
Heyman Richard A.	Director	Oct 04 '24	Proposed Sale	25.51	2,540	64,795		Oct 04 04:28 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 01 '24	Sale	27.54	527	14,512	1,077,409	Oct 03 06:47 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 01 '24	Sale	27.54	526	14,485	1,048,729	Oct 03 06:45 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 01 '24	Option Exercise	2.48	521	1,292	521	Oct 03 06:44 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 01 '24	Sale	27.54	521	14,347	0	Oct 03 06:44 PM
Heyman Richard A.	Director	Oct 01 '24	Sale	27.54	518	14,264	128,585	Oct 03 06:43 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 27 '24	Option Exercise	2.48	4,250	10,540	4,250	Oct 01 07:53 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 30 '24	Option Exercise	2.48	2,000	4,960	2,000	Oct 01 07:53 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 27 '24	Sale	24.27	4,250	103,161	0	Oct 01 07:53 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 30 '24	Sale	25.33	2,000	50,668	0	Oct 01 07:53 PM
Hohl Benjamin	Officer	Oct 01 '24	Proposed Sale	25.54	12,009	306,710		Oct 01 04:14 PM
Hohl Benjamin	Officer	Sep 30 '24	Proposed Sale	24.13	491	11,848		Sep 30 04:19 PM
Heyman Richard A.	Director	Sep 16 '24	Sale	22.41	1,270	28,458	129,103	Sep 18 04:17 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Aug 29 '24	Sale	22.49	12,000	269,841	1,077,936	Sep 03 05:43 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 27 '24	Option Exercise	2.48	4,250	10,540	4,250	Aug 29 06:36 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 27 '24	Sale	22.54	4,250	95,782	0	Aug 29 06:36 PM
Kintz Samuel	PRESIDENT AND CEO	Aug 26 '24	Sale	22.89	12,000	274,718	1,049,255	Aug 28 07:48 PM
Heyman Richard A.	Director	Aug 15 '24	Sale	23.25	1,270	29,526	130,373	Aug 19 07:49 PM
Kintz Samuel	Member of immediate family of	Aug 19 '24	Proposed Sale	23.71	30,000	711,300		Aug 19 04:32 PM
Kintz Samuel	Member of immediate family of	Aug 19 '24	Proposed Sale	23.71	30,000	711,300		Aug 19 04:32 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jul 31 '24	Sale	27.56	3,099	85,399	1,089,936	Aug 02 07:26 PM
Kintz Samuel	PRESIDENT AND CEO	Jul 31 '24	Sale	27.56	2,270	62,555	1,061,255	Aug 02 07:25 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 31 '24	Option Exercise	2.48	991	2,458	991	Aug 02 07:23 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 31 '24	Sale	27.53	991	27,281	0	Aug 02 07:23 PM
Heyman Richard A.	Director	Jul 31 '24	Sale	27.51	1,702	46,815	131,643	Aug 02 07:22 PM
Heyman Richard A.	Director	Jul 31 '24	Sale	27.50	649	17,848	27,918	Aug 02 07:22 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jul 29 '24	Sale	26.70	12,000	320,378	1,093,035	Jul 31 07:33 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 29 '24	Option Exercise	2.48	5,250	13,020	5,250	Jul 31 07:31 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 29 '24	Sale	26.68	5,250	140,052	0	Jul 31 07:31 PM
Heyman Richard A.	Director	Jul 31 '24	Proposed Sale	26.13	649	16,958		Jul 31 04:57 PM
Heyman Richard A.	Director	Jul 31 '24	Proposed Sale	26.13	5,045	131,826		Jul 31 04:31 PM
Hohl Benjamin	Officer	Jul 31 '24	Proposed Sale	26.13	11,000	287,430		Jul 31 04:30 PM
Lyssikatos Joseph P	Officer	Jul 31 '24	Proposed Sale	26.13	65,000	1,698,450		Jul 31 04:23 PM
Kintz Samuel	Officer	Jul 31 '24	Proposed Sale	26.13	47,709	1,246,636		Jul 31 04:22 PM
Kintz Samuel	PRESIDENT AND CEO	Jul 25 '24	Sale	24.92	12,000	299,073	1,063,525	Jul 29 05:39 PM
Hohl Benjamin	Officer	Jul 29 '24	Proposed Sale	27.31	5,250	143,378		Jul 29 04:15 PM
Lyssikatos Joseph P	Officer	Jul 29 '24	Proposed Sale	27.31	12,000	327,720		Jul 29 04:06 PM
Heyman Richard A.	Director	Jul 15 '24	Sale	24.80	1,270	31,497	133,345	Jul 17 07:25 PM
Patel Anish	CHIEF OPERATING OFFICER	Jul 15 '24	Sale	25.05	30,978	776,039	345,574	Jul 16 05:37 PM
Patel Anish	CHIEF OPERATING OFFICER	Jul 12 '24	Sale	25.07	17,475	438,095	376,552	Jul 16 05:37 PM
Patel Anish	CHIEF OPERATING OFFICER	Jul 16 '24	Sale	25.01	1,547	38,692	344,027	Jul 16 05:37 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 12 '24	Option Exercise	2.48	3,000	7,440	3,000	Jul 16 05:34 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 12 '24	Sale	25.07	3,000	75,195	0	Jul 16 05:34 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jul 01 '24	Sale	22.89	12,000	274,736	1,105,035	Jul 03 04:31 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 27 '24	Option Exercise	2.48	4,250	10,540	4,250	Jul 01 08:03 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 27 '24	Sale	22.57	4,250	95,922	0	Jul 01 08:03 PM
Kintz Samuel	PRESIDENT AND CEO	Jun 25 '24	Sale	21.66	12,000	259,902	1,075,525	Jun 27 04:35 PM
Heyman Richard A.	Director	Jun 17 '24	Sale	21.48	1,270	27,278	134,615	Jun 20 07:20 PM
Patel Anish	CHIEF OPERATING OFFICER	Jun 06 '24	Option Exercise	2.48	1,133	2,810	1,133	Jun 10 06:46 PM
Patel Anish	CHIEF OPERATING OFFICER	Jun 06 '24	Sale	20.06	1,133	22,722	0	Jun 10 06:46 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 29 '24	Option Exercise	1.12	12,000	13,440	12,000	May 31 04:05 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	May 29 '24	Sale	21.73	12,000	260,800	0	May 31 04:05 PM
Kintz Samuel	PRESIDENT AND CEO	May 28 '24	Option Exercise	1.12	12,000	13,440	12,000	May 30 05:56 PM
Kintz Samuel	PRESIDENT AND CEO	May 28 '24	Sale	23.18	12,000	278,210	0	May 30 05:56 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	May 28 '24	Option Exercise	2.48	4,250	10,540	4,250	May 30 05:54 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	May 28 '24	Sale	23.18	4,250	98,530	0	May 30 05:54 PM
Heyman Richard A.	Director	May 16 '24	Sale	23.74	1,270	30,150	135,885	May 20 07:46 PM
Gupta Rishi	Director	May 16 '24	Sale	22.14	1,033,300	22,877,262	254,814	May 20 05:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELVN

Enliven Therapeutics Inc

Upgrade your FINVIZ experience